Results 91 to 100 of about 41,281 (176)

Nirmatrelvir/Ritonavir Efficacy in Immunocompetent Patients with Confirmed Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2: An Updated Systematic Review and Meta-analysis. [PDF]

J Res Pharm Pract
Khani E, Afsharirad H, Yadegari AT, Zarezadeh M, Asham H, Bannazadeh-Baghi H, Entezari-Maleki T.   +6 more
europepmc   +1 more source

Pharmacokinetic drug-drug interaction between the COVID-19 3CL protease inhibitor GST-HG171 and itraconazole in healthy subjects. [PDF]

Antimicrob Agents Chemother
Li X, Li B, Wang M, Wang J, Lu J, Mao J, Zhang T, Tang Y, Yan W, Li C, Zhang G, Ding Y.   +11 more
europepmc   +1 more source

A Phase 1 Multiple-Dose, Open-Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women. [PDF]

Clin Transl Sci
Gerhart J, Cheruvu N, Pelletier K, Matschke K, Shi H, Mfopou JK, Hammond J, Singh RSP.   +7 more
europepmc   +1 more source

Patient Characteristics and Healthcare Resource Use among Patients With COVID-19 Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID™) in the Kingdom of Saudi Arabia. [PDF]

Pulm Ther
Alraddadi BM, Almaghrabi RS, Bosaeed M, Kamal M, Hassanien A, Hammam H, Zanotti G, Ikizler BK, d'Hellencourt FL, Spinardi JR, Wang L, Kyaw MH.   +11 more
europepmc   +1 more source

The Impact of the Core-Shell Fiber Composition on the Properties and Stability of the Electrospun Films

Nanotechnology, Science and Applications
Ewelina Łyszczarz,1 Aleksandra Rezka,1 Dorota Majda,2 Witold Jamróz,1 Aleksander Mendyk1 1Chair of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Cracow, Lesser Poland Voivodeship,
Łyszczarz E, Rezka A, Majda D, Jamróz W, Mendyk A   +4 more
doaj  

Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT). [PDF]

BMJ Open
Campbell S, Beaney K, Hosking J, Sorrell L, Allgar V, Aspinall PJ, Ammoun S, Evans DG, Hanemann CO, Kingdon S.   +9 more
europepmc   +1 more source

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection. [PDF]

J Antimicrob Chemother
Khoo SH, FitzGerald R, Edwards CJ, Ahmad S, Saunders G, Else LJ, Shaw V, Mozgunov P, Northey J, Dickinson L, Knox E, Buadi A, Hale C, Reynolds HE, Middleton C, Bullock K, Walker L, Walker L, Tetlow M, Lyon R, Gibney J, Amara A, Greenhalf W, Burdon A, Dixon J, Jaki T, Chiong J, Lalloo DG, Owen A, Jacobs M, Fletcher T, Griffiths G, AGILE CST-8 study group .   +32 more
europepmc   +1 more source

QT interval prolongation and its related factors before and after receiving lopinavir-ritonavir in the COVID-19 era: a historical cohort study. [PDF]

Virus Res
Jangjou A, Izadpanah P, Moqhadas M, Faramarzi H, Fahimi MH, Ghazipoor H, Hamrah H, Kamyab H.   +7 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens. [PDF]

Pharmaceutics
Chen L, Wang X, Li L, Yang Y, Liu Y, Chen W.   +5 more
europepmc   +1 more source

A study on the stability of ritonavir form III processed in orbit and returned to Earth. [PDF]

NPJ Microgravity
Bauser HC, Smith PA, Parent SD, Chan LR, Bhavsar AS, Condon KH, McCalip A, Croom JM, Purcell DK, Bogdanowich-Knipp SJ, Smith DT, Cowans BA, Alajlouni R, Byrn SR, Radocea A.   +14 more
europepmc   +1 more source